TGTX – tg therapeutics, inc. (US:NASDAQ)
Stock Stats
News
4/18
02:12 pm
tgtx
Low
TG Therapeutics, Inc. (NASDAQ: TGTX) had its "buy" rating re-affirmed by analysts at LADENBURG THALM/SH SH. They now have a $39.00 price target on the stock.
4/18
02:12 pm
tgtx
Low
TG Therapeutics, Inc. (NASDAQ: TGTX) had its "overweight" rating re-affirmed by analysts at JPMorgan Chase & Co.. They now have a $25.00 price target on the stock.
4/18
02:12 pm
tgtx
Low
TG Therapeutics, Inc. (NASDAQ: TGTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $45.00 price target on the stock.
4/18
07:30 am
tgtx
Low
TG Therapeutics Announces Additional Data Presentations for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
4/18
07:23 am
tgtx
Low
TG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple Sclerosis [Yahoo! Finance]
2/28/2024
07:00 am
tgtx
18.3%
BEAT
11/1/2023
07:30 am
tgtx
28.9%
BEAT
4/18
02:12 pm
Reiterates
Overweight
Overweight
JPMorgan Chase & Co.
Low
-1.6%
4/18
02:12 pm
Reiterates
Buy
Buy
HC Wainwright
Low
-1.6%
4/18
01:28 pm
Reiterates
Overweight
Overweight
JP Morgan
Low
-2.3%
4/18
01:25 pm
Reiterates
Buy
Buy
Ladenburg Thalmann
Low
-2.3%
2/29
06:08 am
Maintains
Neutral
Neutral
Goldman Sachs
Low
-2.2%
4/29
05:04 pm
tgtx
Low
Form ARS TG THERAPEUTICS, INC. For: Dec 31
4/29
04:36 pm
tgtx
Low
Form DEFA14A TG THERAPEUTICS, INC.
4/29
04:34 pm
tgtx
Low
Form DEF 14A TG THERAPEUTICS, INC. For: Jun 14
4/18
04:57 pm
tgtx
Low
Form PRE 14A TG THERAPEUTICS, INC. For: Jun 04
3/15
04:44 pm
tgtx
Low
Form 4 TG THERAPEUTICS, INC. For: Mar 13 Filed by: Lonial Sagar
Show more
Top News Gainers
12/8 TG Therapeutics Announces Oral Presentation of Umbralisib, Ublituximab and Venetoclax Triple Combination Phase I/II Data in Relapsed/Refractory CLL at the 61st American Society of Hematology Annual Meeting and Exposition 24.6%
12/23 TG Therapeutics Announces $50.0 Million Registered Direct Public Offering of Common Stock to a Single Institutional Investor 15.9%
6/26 TG Therapeutics: Hitting A Growth Inflection [Seeking Alpha] 14.3%
10/28 TG Therapeutics Announces Positive Results from the UNITY-NHL Phase 2b Pivotal Trial Evaluating Umbralisib Monotherapy in Patients with Relapsed/Refractory Follicular Lymphoma 13.2%
4/18 TG Therapeutics Inc (NASDAQ: TGTX) had its "buy" rating re-affirmed by analysts at B. Riley. They now have a $25.00 price target on the stock. 8.9%
6/18 TG Therapeutics to Present at the Raymond James Life Sciences and MedTech Conference 7.5%
3/20 Form 424B5 TG THERAPEUTICS, INC. 7.3%
4/17 TG Therapeutics Inc (NASDAQ: TGTX) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 6.5%
8/29 TG Therapeutics Announces Data Presentations at the Upcoming 35th Annual Congress of ECTRIMS  5.4%
11/8 TG Therapeutics to Host Conference Call on Third Quarter 2019 Financial Results and Business Update 5.1%
Top News Decliners
3/14 TG Therapeutics Inc (NASDAQ: TGTX) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -16.5%
3/7 TG Therapeutics Inc (NASDAQ: TGTX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $15.00 price target on the stock. -15.1%
5/10 Form 10-Q TG THERAPEUTICS, INC. For: May 10 -9.4%
12/6 TG Therapeutics Recaps Schedule of Triple Therapy Data Presentations at the Upcoming 61st American Society of Hematology Annual Meeting and Exposition -8.5%
5/7 TG Therapeutics Announces Long-term Follow-up Data from the Phase 2 Trial of Ublituximab in Patients with Multiple Sclerosis at the American Academy of Neurology 71st Annual Meeting -8.0%
8/22 TG Therapeutics Inc (NASDAQ: TGTX) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -7.2%
5/10 Q1/2019 3/31/2019 EPS -0.430 ZacksConsensus -0.470 ActVsEst 0.040 - Beat -6.8%
1/17 TG Therapeutics Inc (NASDAQ: TGTX) had its price target raised by analysts at HC Wainwright from $20.00 to $24.00. They now have a "buy" rating on the stock. -5.8%
9/5 Form S-3ASR TG THERAPEUTICS, INC. -5.7%
9/20 TG Therapeutics to Present at the Ladenburg Thalmann Healthcare Conference -5.6%
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.
Click Here To Register For The Live Online Workshop
In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview
Earnings Week Wrap-up and Takeaways
Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix
Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More
The Smart Way to Ten Minutes Per Day

Information

Support

Contact us

20715 N Pima Rd #F108
Scottsdale, AZ 85255
Email: info@newsquantified.com
Copyright Ⓒ News Quanitifed LLC. 1.1.3